Breakthrough Genomics & EpigeneticsRx Partner to Further Functional...
pharmatechoutlook

Breakthrough Genomics & EpigeneticsRx Partner to Further Functional Genomic Analysis and Innovations for the Medical Industry

By Pharma Tech Outlook | Monday, December 16, 2019

“Patients and Providers need an easy, affordable way to understand their genetic data, monitor their health outcomes and obtain vetted personalized products. Our partnership with Breakthrough Genomics will assure all users have access to actionable genomic data designed to be used within a medical setting,” states Deb Hubers, CEO of EpigeneticsRx.

EpigeneticsRx’s platform is built on functional genomics, directed by licensed healthcare providers. The partnership capitalizes on EpigeneticsRx's base of 25,000+ patients and 2,500+ healthcare professionals (HCP), as well as both companies’ years of experience in clinical and functional genomics.

"When working with medical providers, the need for reliable data interpretation that can be brought to scale is critical in making sure the diagnosis is accurate, timely, and based on up-to-date scientific evidence,” says Laura Li, CEO and Founder of Breakthrough Genomics.

The partnership was founded on the mutual mission of assuring the medical industry has access to the most efficacious and actionable functional genomic data. The partnership is also an example of how “Women in STEM” are actively working to innovate within the rapidly growing field of precision medicine.

Dr. Kulvi Kaur, Chief Scientific Officer of EpigeneticsRx, adds “Functional genomics focuses on the interplay of the various genetic markers rather than focusing on a single mutation. The importance of using credible clinical data and having a reliable platform to analyze the data is a key component to improving patient care.”

Weekly Brief